Sokal Index for Chronic Myelogenous Leukaemia
Sokal risk index for predicting survival in CML treated with conventional chemotherapy. Stratifies into low, intermediate, and high risk. Used less commonly now with TKI therapy but still referenced.
Score interpretation
→ Sokal Low Risk (<0.8): Favourable prognosis. Standard-dose imatinib or 2nd-generation TKI (dasatinib, nilotinib) as first-line. Molecular response monitoring (BCR-ABL at 3, 6, 12 months); aim for MR3 (MMR) by 12 months.
→ Sokal Intermediate Risk (0.8–1.2): Intermediate prognosis. Consider 2nd-generation TKI (dasatinib or nilotinib) for faster/deeper molecular responses. BCR-ABL monitoring; haematology review 3-monthly.
→ Sokal High Risk (>1.2): Adverse prognosis on conventional therapy. 2nd-generation TKI preferred over imatinib (better molecular response rates at high Sokal); monitor closely; consider clinical trial; assess for MR4.5 for TKI-free remission candidacy.
Interpretation bands for the Sokal CML Index. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for Colorectal Cancer Recurrence · Oncology
- CRASH Score for Chemotherapy Risk Assessment in Elderly Patients · Oncology
- Ann Arbor Staging System for Lymphoma · Oncology
- Rai Staging System for CLL · Oncology
- Follicular Lymphoma International Prognostic Index (FLIPI) · Oncology
- International Staging System for Multiple Myeloma (ISS) · Oncology
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Febuxostat · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.